The xc - Cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: Use of sulfasalazine

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 463-472

  Guan, Jun ^a   Lo, Maisie ^a   Dockery, Peter ^b   Mahon, Sarah ^b   Karp, Cristina M ^c   Buckley, Arthur R ^d   Lam, Stephen ^a   Gout, Peter W ^a   Wang, Yu Zhuo ^a,e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cystine; Glutathione; SCLC xenograft model; Small cell lung cancer; Sulfasalazine; Xc transporter

Indexed keywords

ANTIPORTER; CYSTINE GLUTAMATE ANTIPORTER; GLUTAMATE SODIUM; GLUTATHIONE; MERCAPTOETHANOL; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; CYSTINE; NONSTEROID ANTIINFLAMMATORY AGENT; SLC7A11 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; TUMOR XENOGRAFT; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; IC 50; LUNG TUMOR; METABOLISM; MOUSE MUTANT; PATHOLOGY; SMALL CELL CARCINOMA; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL TRANSPORT; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CYSTINE; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; SODIUM GLUTAMATE; SULFASALAZINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67349136816     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0894-4     Document Type: Article

References (37)

1. S Sun JH Schiller M Spinola JD Minna 2007 New molecularly targeted therapies for lung cancer J Clin Invest 117 2740 2750 (Pubitemid 47529602)
2. GR Simon A Turrisi 2007 Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 324S 339S (Pubitemid 47505212)
3. CL Hann CM Rudin 2007 Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer Trends Mol Med 13 150 157 (Pubitemid 46498831)
4. PW Gout YJ Kang DJ Buckley N Bruchovsky AR Buckley 1997 Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells Leukemia 11 1329 1337 (Pubitemid 27387312)
5. - cystine transporter: a new action for an old drug Leukemia 15 1633 1640 (Pubitemid 32994684)
6. VS Narang GM Pauletti PW Gout DJ Buckley AR Buckley 2003 Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells Anticancer Res 23 4571 4579 (Pubitemid 38173869)
7. DW Doxsee PW Gout T Kurita M Lo AR Buckley Y Wang H Xue CM Karp JC Cutz GR Cunha YZ Wang 2007 Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy Prostate 67 162 171 (Pubitemid 46185319)
8. - cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance Br J Cancer 99 464 472
9. S Bannai 1986 Exchange of cystine and glutamate across plasma membrane of human fibroblasts J Biol Chem 261 2256 2263 (Pubitemid 17205155)
10. PW Gout CR Simms MC Robertson 2003 In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine Anticancer Drugs 14 21 29 (Pubitemid 36177351)
11. - cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases J Cell Physiol 215 593 602 (Pubitemid 351632680)
12. AL Edinger CB Thompson 2002 Antigen-presenting cells control T cell proliferation by regulating amino acid availability Proc Natl Acad Sci USA 99 1107 1109 (Pubitemid 34136454)
13. JM Estrela A Ortega E Obrador 2006 Glutathione in cancer biology and therapy Crit Rev Clin Lab Sci 43 143 181 (Pubitemid 43860449)
14. OW Griffith 1999 Biologic and pharmacologic regulation of mammalian glutathione synthesis Free Radic Biol Med 27 922 935 (Pubitemid 29507466)
15. VS Narang GM Pauletti PW Gout DJ Buckley AR Buckley 2007 Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin Chemotherapy 53 210 217 (Pubitemid 46581995)
16. T Voskoglou-Nomikos JL Pater L Seymour 2003 Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin Cancer Res 9 4227 4239 (Pubitemid 37204044)
17. NE Sharpless RA Depinho 2006 The mighty mouse: genetically engineered mouse models in cancer drug development Nat Rev Drug Discov 5 741 754 (Pubitemid 44323701)
18. Y Wang H Xue JC Cutz J Bayani NR Mawji WG Chen LJ Goetz SW Hayward MD Sadar CB Gilks PW Gout JA Squire GR Cunha YZ Wang 2005 An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line Lab Invest 85 1392 1404 (Pubitemid 41509387)
19. JC Cutz J Guan J Bayani M Yoshimoto H Xue M Sutcliffe J English J Flint J LeRiche J Yee JA Squire PW Gout S Lam YZ Wang 2006 Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes Clin Cancer Res 12 4043 4054 (Pubitemid 44078092)
20. TM Mayhew 1991 The new stereological methods for interpreting functional morphology from slices of cells and organs Exp Physiol 76 639 665
21. Howard CV, Reed MG (2005) Unbiased stereology. Bios Scientific Publishers, Oxford, pp 256-277
22. P Dockery J Fraher 2007 The quantification of vascular beds: a stereological approach Exp Mol Pathol 82 110 120 (Pubitemid 46483383)
23. JO Rosado M Salvador D Bonatto 2007 Importance of the trans-sulfuration pathway in cancer prevention and promotion Mol Cell Biochem 301 1 12 (Pubitemid 46895141)
24. JR Uren H Lazarus 1979 l-cyst(e)ine requirements of malignant cells and progress toward depletion therapy Cancer Treat Rep 63 1073 1079 (Pubitemid 10220107)
25. F Verrey EI Closs CA Wagner M Palacin H Endou Y Kanai 2004 CATs and HATs: the SLC7 family of amino acid transporters Pflugers Arch 447 532 542 (Pubitemid 38258215)
26. T Ishii S Bannai Y Sugita 1981 Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine J Biol Chem 256 12387 12392
27. E Guastavino NH Litwin L Heffes Nahmod R Licastro 1988 Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment Acta Gastroenterol Latinoam 18 107 113
28. H Gmunder HP Eck W Droge 1991 Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones Eur J Biochem 201 113 117
29. U Klotz 1985 Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid Clin Pharmacokinet 10 285 302 (Pubitemid 15005992)
30. WJ Chung SA Lyons GM Nelson H Hamza CL Gladson GY Gillespie H Sontheimer 2005 Inhibition of cystine uptake disrupts the growth of primary brain tumors J Neurosci 25 7101 7110 (Pubitemid 41113926)
31. RJ Rodenburg A Ganga PL van Lent LB van de Putte WJ van Venrooij 2000 The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis Arthritis Rheum 43 1941 1950 (Pubitemid 30953256)
32. L Bingle NJ Brown CE Lewis 2002 The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies J Pathol 196 254 265 (Pubitemid 34189413)
33. JD Lay CC Hong JS Huang YY Yang CY Pao CH Liu YP Lai GM Lai AL Cheng IJ Su SE Chuang 2007 Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL Cancer Res 67 3878 3887
34. C Wahl S Liptay G Adler RM Schmid 1998 Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B J Clin Invest 101 1163 1174 (Pubitemid 28125296)
35. T Schnelldorfer S Gansauge F Gansauge S Schlosser HG Beger AK Nussler 2000 Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells Cancer 89 1440 1447 (Pubitemid 30727208)
36. K Davison S Cote S Mader WH Miller 2003 Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines Leukemia 17 931 940 (Pubitemid 36626322)
37. Y Huang Z Dai C Barbacioru W Sadee 2005 Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance Cancer Res 65 7446 7454 (Pubitemid 41161279)